Naglazyme (galsulfase) Coverage Criteria
Customize your policy alerts
Sign up for Molina Healthcare Policy C28288-A alerts
Get alerted when Policy C28288-A changes without checking for updates manually.
Monitor payer policy activity
This policy governs prior authorization and coverage criteria for intravenous Naglazyme (galsulfase) for members with Mucopolysaccharidosis VI (MPS VI; Maroteaux-Lamy syndrome). Coverage depends on benefit eligibility, medical necessity, required documentation, specialist involvement, age, dosing, and site-of-care requirements.
The Q3 2026 revision updated the references and revised required medical information, continuation-of-therapy requirements, and quantity provisions.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.